CK7+/TTF-1+/CDX2-/CK20- Strongly Supports Primary Lung Adenocarcinoma
A tumor that is CK7-positive, TTF-1-positive, CDX2-negative, and CK20-negative is highly consistent with primary lung adenocarcinoma and effectively rules out colorectal origin. This immunoprofile represents the classic pattern for lung adenocarcinoma and is the opposite of what you would see in metastatic colorectal cancer 1.
Immunohistochemical Interpretation
The combination of markers you describe creates a definitive diagnostic pattern:
Primary Lung Adenocarcinoma Profile (Your Case)
- TTF-1: Positive - Highly specific for lung origin (75-80% sensitivity for lung adenocarcinoma)
- CK7: Positive - Typical for lung adenocarcinoma
- CK20: Negative - Expected in lung primary
- CDX2: Negative - Confirms non-GI origin
This immunoprofile has >95% specificity for primary lung adenocarcinoma when all four markers align in this pattern 1.
Why This Rules Out Colorectal Origin
Colorectal adenocarcinomas demonstrate the exact opposite immunoprofile 1:
- TTF-1: Negative
- CK7: Negative
- CK20: Positive
- CDX2: Positive
The CDX2-negative and CK20-negative findings are particularly important because CDX2 is highly specific for GI tract origin (98% specificity for GI neuroendocrine tumors, and similarly high for adenocarcinomas), and colorectal cancers are characteristically CK20-positive 1, 2.
Clinical Significance
Diagnostic Certainty
The American College of Chest Physicians guidelines specifically recommend using this directed immunohistochemical panel to differentiate primary lung carcinoma from metastatic disease, with Grade 1C evidence 1. Your case demonstrates textbook concordance with primary lung adenocarcinoma.
Management Implications
This diagnosis has critical implications for:
- Staging: Treat as primary lung cancer staging system
- Molecular testing: Pursue lung cancer-specific molecular markers (EGFR, ALK, ROS1, PD-L1, etc.)
- Treatment planning: Use lung cancer treatment algorithms, not colorectal protocols
- Prognosis: Apply lung adenocarcinoma prognostic models
Important Caveats
Rare Exceptions to Be Aware Of
While extremely uncommon, be aware that:
Aberrant TTF-1 expression has been reported in metastatic colorectal cancer in rare cases, but these tumors maintain their CK20+/CDX2+ profile 3. Your case's CK20-/CDX2- pattern excludes this pitfall.
CK7-negative lung adenocarcinomas exist but are uncommon (~20-25% of cases) 4. However, when TTF-1 is positive alongside CK7, the diagnosis of lung primary is essentially certain.
Pulmonary enteric adenocarcinoma (PEA) is a rare lung primary that mimics colorectal cancer histologically, but even these unusual tumors are typically CDX2-positive 4. Your CDX2-negative result argues against PEA.
Additional Markers to Consider
If diagnostic uncertainty persists (though it shouldn't with this profile), consider:
- Napsin A: Positive in 80-85% of lung adenocarcinomas, negative in colorectal cancer 5
- SATB2: Highly specific for colorectal origin when positive 3
Algorithmic Approach
For CK7+/TTF-1+ tumors:
- If CDX2- and CK20- → Primary lung adenocarcinoma (your case)
- If CDX2+ and CK20+ → Consider rare aberrant TTF-1 expression in metastatic colorectal cancer; correlate with clinical history
- If mixed pattern → Add Napsin A and SATB2 to panel
Your specific immunoprofile (CK7+/TTF-1+/CDX2-/CK20-) has approximately 93-95% diagnostic accuracy for primary lung adenocarcinoma based on the guideline evidence 1.